Basilea Entered into an Asset Purchase and Sub-License Agreement with SillaJen for BAL0891
Shots:
- Basilea will receive upfront and near-term milestones of $14M & is also eligible to receive ~$320M upon achievement of predefined development, regulatory, and sales milestones along with royalties on net sales. In 2018, Basilea acquired a license for BAL0891 from Dutch precision medicine firm NTRC
- Under the asset purchase agreement, SillaJen receives IP rights & sub-licensing rights from Basilea upon the license and collaboration agreement with NTRC
- The agreement will advance the BAL0891 for patients suffering from advanced solid tumors. BAL0891 targets both TTK and PLK1 kinases & is designed for the development of multiple cancers
Ref: Globenewswire | Image: Basilea
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
